GAITHERSBURG, Md.--Genomics services company Oncormed completed a $3 million equity financing through a private placement of convertible preferred stock to certain investors. Subject to certain conditions, the company and investors have the right to increase the aggregate amount of equity financing by an additional $3 million for an aggregate investment of $6 million. Oncormed characterizes genes to establish their clinical relevance and provides molecular profiling of patients for pharmacogenomic and therapeutic purposes.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.